Clinical trial
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
NCT00196768 · German AML Cooperative Group, Other · Unknown status
Key facts
| NCT number | NCT00196768 |
|---|---|
| Title | Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic |
| Official title | Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) |
| Lead sponsor | German AML Cooperative Group, Other |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsed Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia |
| Intervention type | Drug |
| Interventions | Arsenic trioxide, Trisenox |
| Enrollment | 30 |
| Start date | Jan 1, 2005 |
| Completion | Dec 1, 2010 |
| First posted | Sep 20, 2005 |
| Last update posted | Oct 23, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: